IPO - ABVC BIOPHARMA, INC.

Form Type: POS AM

Filing Date: 2025-05-27

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025047464

Filing Summary: ABVC BioPharma, Inc. filed a Post-Effective Amendment No. 6 to its Registration Statement on Form S-1, previously effective on December 23, 2020. This amendment integrates information from its 10-Q report for the quarter ended March 31, 2025, and its 10-K report for the fiscal year ended December 31, 2024. It details the initiation of several clinical trials related to its drug development portfolio, including ongoing Phase I/II studies for multiple cancer treatments and a significant focus on botanical drugs aimed at addressing unmet medical needs in CNS and oncology. The amendment confirms the registration of 3,400,187 shares of Common Stock for resale by selling stockholders, updates their table, and notes this offering as ongoing. The Company, incorporated in Nevada, identifies as a smaller reporting company and an emerging growth company, highlighting its growth strategy through licensing and collaboration. Recent notifications from Nasdaq indicate challenges with minimum bid price and stockholders' equity compliance, necessitating adherence to listing standards to avoid delisting procedures.

Form Type: POS AM

Filing Date: 2025-05-27

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025047471

Filing Summary: This document is a Post-Effective Amendment No. 4 to the Registration Statement on Form S-1 for ABVC Biopharma, Inc. It updates the registration statement initially declared effective on August 2, 2021. The amendment relates to the registration of 2,255,000 shares of common stock underlying warrants previously issued in conjunction with the August 2021 public offering. This offering does not involve the direct sale of shares by the company, as all net proceeds will go to warrant holders upon exercise. The document states expected continuation of the company’s focus on biopharmaceutical solutions, with a mission to address substantial unmet medical needs through innovative botanical drugs targeting CNS and oncology diseases. It updates certain information based on the company's quarterly and annual reports filed with the SEC and reiterates compliance requirements for continued listing on NASDAQ, specifically addressing past deficiencies in stockholder equity, and the steps taken to regain compliance.

Form Type: POS AM

Filing Date: 2025-05-27

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025047480

Filing Summary: On May 27, 2025, ABVC BioPharma, Inc. filed a Post-Effective Amendment No. 1 to their Form S-1 registration statement with the SEC to update and supplement information related to their earlier effective registration statement as of July 1, 2024. The filing pertains to the registration of up to 1,000,000 shares of Common Stock, which includes shares underlying a Common Stock Purchase Warrant from a prior agreement with Lind Global Fund II, LP. The prospectus outlines the offering of these securities, which will permit the selling stockholders to sell shares in the public market. Additionally, it includes recent developments and trials in their drug development pipeline, underlining the ongoing focus on addressing significant medical needs with innovative therapies. There are no new securities being registered in this amendment, and all relevant registration fees have already been paid. The summary also highlights that the company operates in the biotechnology sector with an emphasis on therapeutic solutions for CNS and oncology-related conditions, backed by substantial clinical trial collaborations across North America and Asia-Pacific.

Form Type: POS AM

Filing Date: 2025-05-16

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025044880

Filing Summary: ABVC BioPharma, Inc. filed a Post-Effective Amendment No. 1 to Form S-1, updating the registration statement to include details on the resale of up to 11,714,683 shares of Common Stock. This includes shares linked to secured, convertible notes and common stock purchase warrants stemming from multiple transactions with Lind Global Fund II, LP. The document emphasizes that the selling stockholders may sell their shares at prevailing market prices without a set termination date for the offering. The amendment does not introduce new securities for registration, aligns with previously paid registration fees, and restates the purpose of effectiveness in compliance with SEC regulations. Notably, the stock's recent trading price was reported to be $1.46 per share, with the company also addressing compliance issues related to Nasdaq listing rules, particularly regarding share pricing and stockholder equity requirements. This document also incorporates previous reports including quarterly and annual results that may influence investor decisions regarding the offerings.

Form Type: POS AM

Filing Date: 2025-05-16

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025044891

Filing Summary: ABVC BioPharma, Inc. filed a Post-Effective Amendment No. 1 to Form S-1 on May 16, 2025. This amendment pertains to the resale of up to 11,714,683 shares of Common Stock held by certain selling stockholders. The shares include those underlying secured convertible notes and common stock purchase warrants from several securities purchase agreements with Lind Global Fund II, LP. This registration aims to allow these stockholders to sell their shares in the public market, acknowledging the evolving nature of the Company’s capital structure and ongoing compliance requirements with the SEC, particularly concerning its registration statements filed on April 24, 2023. The Company is positioned as a non-accelerated filer and smaller reporting company, with an emphasis on developing a pipeline of innovative therapeutic solutions addressing significant unmet medical needs. The closing price of the common stock was reported at $1.46 per share on May 14, 2025, and the document underscores the potential risks associated with investing in ABVC securities, as well as the Company’s compliance challenges with Nasdaq listing rules.